[ISR’s “Central Lab Market Dynamics and Outsourcing Performance” report surveyed 101 respondents with decision-making authority for central lab services.]
Expected growth of central lab service areas
Respondents indicated that the central lab services projected to see the most growth over the next three years are biomarkers and genomics . Specifically, “biomarkers from Phase IIb through commercialization” is expected to experience the largest rate of growth.
Regional distribution
Based on feedback from industry experts, ISR’s report asked several different types of questions surrounding the historic, current and future geographical mix of central lab activities.
From a macro point of view, the distribution of central lab testing shows a substantial drop in testing in North America and modest gains in emerging pharma regions. With that being said, respondents indicate that the majority of central lab tests (72%) will continue to be run in North America and Western Europe through 2015.
To dive a little deeper, ISR asked respondents to indicate which countries they had been using more of today as compared to two years ago and which countries they had been using less of two years ago compared to today. Results show that China has seen the largest increase in net usage (from 4% to 20%), while North America has experienced a slight decrease in net usage (28% to 27%). One important finding from these two
questions is that respondents are indicating they are performing central lab tests in more countries as the vast majority of countries are showing a net increase in usage.
Attributes sponsors use to select central lab providers
With over half of the respondents surveyed indicating that ALL of their central lab activities are outsourced, attributes sponsors use to select service providers are more important than ever.
In selecting a central lab service provider, respondents indicated that “Quality” (34%) is the single, most important attribute. When respondents were asked to select their top 5 most important attributes for selection, “Quality” (65%) was followed closely by “Sample turnaround time” (56%).
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.